To discover the importance of electrochemotherapy for the treatment of cutaneous and subcutaneous tumours, and to find out more about the functions of the Cliniporator, for an efficacious and safe treatment with minimal side effects, visit the dedicated oncology section.
-
Symposium on Electrochemotherapy
During the XIX Conference Polish Society Surgical Oncology in Gdansk, IGEA will sponsor a symposium on Electrochemotherapy on Friday 24th May 2013, 13.15 – 14.15.
-
An “e-session” on Electrochemotherapy
The European School of Oncology in co-operation with Nature Reviews in Clinical Oncology and CriticalReviews in Oncology Hematology is holding a series of distance learning programmes on the Internet, called “e-sessions”: e-grandrounds and oncoreviews.
We are pleased to inform you that on July 25th 2013 from 6.15 to 7.00 pm there will be an “e-session” held by doctor Alessandro Testori (Director of Melanoma – Sarcoma Division – IEO Milan) on Electrochemotherapy.
-
Electrochemotherapy: NICE guidance for metastasis in the skin
Electrochemotherapy receives NICE (National Institute for Health and Clinical Excellence – UK) positive guidance for metastasis in the skin (for tumours of non skin origin and melanoma), and for primary basal cell carcinoma and primary squamous cell carcinoma.
This is a very important achievement that confirms effectiveness and safety of Electrochemotherapy.
-
2nd International Users' Meeting, the report
The Electrochemotherapy Users' Meeting that was held in Bologna March 1st-2nd was a true success.
75 speakers in 17 scientific sessions talked about the latest clinical results in front of an audience of over 300 delegates from 20 different countries.
-
IGEA Worldwide
Since 1980, the year it was founded, IGEA has been working to provide patients with effective therapies.
Research and intellectual curiosity have always distinguished the work of IGEA, and over the years have enabled IGEA to become the leading company in the field of Clinical Biophysics. Individuals and their ideas, knowledge built on a solid scientific foundation and product quality are the foundation on which IGEA decided to build its future.
-
Oncology
IGEA works on the treatment of cutaneous and subcutaneous tumours of electrochemotherapy, an efficacious technique that can guarantee that drugs and genetic material can penetrate the poorly permeable tumour cell.
Its use is particularly indicated in patients with local recurrences or cutaneous metastases of breast cancer, head of neck cancers and stage III B/C and IV M1 melanoma.
-
Orthopaedics
IGEA's aim is to make the best technology to cure the patient, available to the clinician, through the many applications of Clinical Biophysics, designed to promote the reparative processes in bone tissue and cartilage.
Major clinical studies have demonstrated the efficacy of IGEA medical devices in noticeably reducing fracture healing times, without resorting to surgical procedures.
-
Customer help service
Professionalism and expertise resulting from more than 30 years of activity and experience in the field, but also passion and courtesy in assisting patients right from the first phone call.
The qualified personnel of IGEA's Customer Help Service is always available to resolve, by phone or e-mail, any doubts or questions patients have, and assist them in the use of IGEA devices.
